NewEdge Wealth LLC Sells 2,950 Shares of Stryker Corporation $SYK

NewEdge Wealth LLC lowered its position in Stryker Corporation (NYSE:SYK) by 26.2% during the 1st quarter, HoldingsChannel reports. The firm owned 8,307 shares of the medical technology company’s stock after selling 2,950 shares during the period. NewEdge Wealth LLC’s holdings in Stryker were worth $2,730,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Godfrey Financial Associates Inc. bought a new stake in Stryker during the fourth quarter valued at $26,000. Sankala Group LLC bought a new position in Stryker in the 4th quarter worth about $26,000. United Financial Planning Group LLC purchased a new stake in shares of Stryker in the 3rd quarter valued at about $27,000. Atlas Capital Advisors Inc. purchased a new stake in shares of Stryker in the 4th quarter valued at about $27,000. Finally, DJE Kapital AG bought a new stake in shares of Stryker during the 4th quarter valued at about $28,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

SYK opened at $330.69 on Friday. The stock has a 50-day moving average price of $314.69 and a 200-day moving average price of $335.66. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.14. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $126.77 billion, a P/E ratio of 38.27, a PEG ratio of 2.12 and a beta of 0.77.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter last year, the company posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts predict that Stryker Corporation will post 14.99 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the sale, the vice president owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 323,264 shares of company stock worth $100,659,489 over the last ninety days. Insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Evercore set a $350.00 price objective on Stryker in a report on Monday, July 6th. Truist Financial reaffirmed a “hold” rating and issued a $330.00 target price (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. BTIG Research set a $371.00 target price on shares of Stryker in a research report on Monday, July 13th. Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a research note on Friday, May 1st. Finally, Barclays decreased their price target on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $392.52.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.